Pulmonary vascular disease & thromboembolismDiagnostic or prognostic study
A Bleeding Risk Score for Cancer-Associated Venous Thromboembolism in Patients Receiving Direct Oral Anticoagulants
- Prediction model development and external validation study
- derivation cohort
- external validation cohort
Authors' conclusion
The ONCO-DOAC BLEED score provides clinically relevant stratification of major bleeding risk in patients with cancer-associated VTE receiving DOAC therapy
Study context
- Population
- Patients with cancer-associated venous thromboembolism (VTE) receiving DOAC therapyderivation cohort
- Participants
- 1,166 patients
- Comparison
- Derivation vs Validation
- Derivationn = 1,166
- Outcome
- Discrimination of the ONCO-DOAC BLEED score for major bleeding
- Follow-up
- Median 163 days
Performance
As reported in the abstract
Discrimination for major bleeding
| Test or model | Harrell's C-index | Uno's C-index |
|---|---|---|
| Derivation | 0.68 | 0.67 |
| Validation | 0.62 | 0.63 |
Further findings
Major bleeding incidence (derivation cohort) · median follow-up 163 days
- Patients with major bleeding
- 127 (10.9%)
Independent predictors of major bleeding (multivariable analysis)
- History of major bleeding, CKD, NSAID use, distant metastatic cancer, terminal cancer, upper GI cancer, pancreatic cancer, uterine cancer
Original publication
A Bleeding Risk Score for Cancer-Associated Venous Thromboembolism in Patients Receiving Direct Oral Anticoagulants. JACC CardioOncol. doi:10.1016/j.jaccao.2026.05.002
Summarised from the published abstract; every number is checked against it